nach oben

Erschienen in:

01.04.2016 | Review

Nesfatin-1: a new energy-regulating peptide with pleiotropic functions. Implications at cardiovascular level

verfasst von: Sandra Feijóo-Bandín, Diego Rodríguez-Penas, Vanessa García-Rúa, Ana Mosquera-Leal, José Ramón González-Juanatey, Francisca Lago

Erschienen in: Endocrine | Ausgabe 1/2016

Einloggen, um Zugang zu erhalten

Abstract

Nesfatin-1 is a new energy-regulating peptide widely expressed at both central and peripheral tissues with pleiotropic effects. In the last years, the study of nesfatin-1 actions and its possible implication in the development of different diseases has created a great interest among the scientific community. In this review, we will summarize nesfatin-1 main functions, focusing on its cardiovascular implications.

T. Basak, S. Varshney, S. Akhtar, S. Sengupta, Understanding different facets of cardiovascular diseases based on model systems to human studies: a proteomic and metabolomic perspective. J. Proteomics. (2015). doi:10.1016/j.jprot.2015.04.027

S.R. Daniels, Prevention of atherosclerotic cardiovascular disease: what is the best approach and how early should we start? J. Am. Coll. Cardiol. 63, 2786–2788 (2014). doi:10.1016/j.jacc.2014.01.082 PubMedCrossRef

WHO Global atlas on cardiovascular disease prevention and control (2011). http://www.who.int/cardiovascular_diseases/publications/atlas_cvd/en/. Accessed 15 July 2015

WHO Cardiovascular diseases (CVDs), Fact Sheet N^o317. (2015). http://www.who.int/mediacentre/factsheets/fs317/en/ Accessed 15 May 2015

T. Bhurosy, R. Jeewon, Overweight and Obesity Epidemic in Developing Countries: a Problem with Diet, Physical Activity, or Socioeconomic Status? ScientificWorldJournal 2014, 964236 (2014). doi:10.1155/2014/964236 PubMedPubMedCentralCrossRef

D. Segula, Complications of obesity in adults: a short review of the literature. Malawi Med. J. 26, 20–24 (2014). http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4062780&tool=pmcentrez&rendertype=abstract. Accessed 9 Jan 2015

P. Poirier, T.D. Giles, G.A. Bray, Y. Hong, J.S. Stern, F.X. Pi-Sunyer et al., Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss. Arterioscler. Thromb. Vasc. Biol. 26, 968–976 (2006). doi:10.1161/01.ATV.0000216787.85457.f3 PubMedCrossRef

A. Hruby, F.B. Hu, The epidemiology of obesity: a big picture. Pharmacoeconomics 33, 673–689 (2014). doi:10.1007/s40273-014-0243-x CrossRef

M. Bastien, P. Poirier, I. Lemieux, J.-P. Després, Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog. Cardiovasc. Dis. 56, 369–381 (2013). doi:10.1016/j.pcad.2013.10.016 PubMedCrossRef

10.

M.M. Ibrahim, Subcutaneous and visceral adipose tissue: structural and functional differences. Obes. Rev. 11, 11–18 (2010). doi:10.1111/j.1467-789X.2009.00623.x PubMedCrossRef

11.

P. Mathieu, M.-C. Boulanger, J.-P. Després, Ectopic visceral fat: a clinical and molecular perspective on the cardiometabolic risk. Rev. Endocr. Metab. Disord. 15, 289–298 (2014). doi:10.1007/s11154-014-9299-3 PubMedCrossRef

12.

S. Cherian, G.D. Lopaschuk, E. Carvalho, Cellular cross-talk between epicardial adipose tissue and myocardium in relation to the pathogenesis of cardiovascular disease. Am. J. Physiol. Endocrinol. Metab. 303, E937–E949 (2012). doi:10.1152/ajpendo.00061.2012 PubMedCrossRef

13.

C.R. Balistreri, C. Caruso, G. Candore, The role of adipose tissue and adipokines in obesity-related inflammatory diseases. Mediators Inflamm. 2010, 802078 (2010). doi:10.1155/2010/802078 PubMedPubMedCentral

14.

H. Mohan, S. Unniappan, Phylogenetic aspects of nucleobindin-2/nesfatin-1., Curr. Pharm. Des. 19, 6929–34 (2013). http://www.ncbi.nlm.nih.gov/pubmed/23537083. Accessed 8 Jan 2014

15.

S. Oh-I, H. Shimizu, T. Satoh, S. Okada, S. Adachi, K. Inoue et al., Identification of nesfatin-1 as a satiety molecule in the hypothalamus. Nature 443, 709–712 (2006). doi:10.1038/nature05162 PubMedCrossRef

16.

G.C. Brailoiu, S.L. Dun, E. Brailoiu, S. Inan, J. Yang, J.K. Chang et al., Nesfatin-1: distribution and interaction with a G protein-coupled receptor in the rat brain. Endocrinology 148, 5088–5094 (2007). doi:10.1210/en.2007-0701 PubMedCrossRef

17.

M. Goebel, A. Stengel, L. Wang, Y. Taché, Central nesfatin-1 reduces the nocturnal food intake in mice by reducing meal size and increasing inter-meal intervals. Peptides 32, 36–43 (2011). doi:10.1016/j.peptides.2010.09.027 PubMedPubMedCentralCrossRef

18.

S. Gaigé, M.S. Bonnet, C. Tardivel, P. Pinton, J. Trouslard, A. Jean et al., c-Fos immunoreactivity in the pig brain following deoxynivalenol intoxication: focus on NUCB2/nesfatin-1 expressing neurons. Neurotoxicology 34, 135–149 (2013). doi:10.1016/j.neuro.2012.10.020 PubMedCrossRef

19.

R. Gonzalez, B. Kerbel, A. Chun, S. Unniappan, Molecular, cellular and physiological evidences for the anorexigenic actions of Nesfatin-1 in goldfish. PLoS One 5, 14 (2010). doi:10.1371/journal.pone.0015201

20.

F. Lin, C. Zhou, H. Chen, H. Wu, Z. Xin, J. Liu et al., Molecular characterization, tissue distribution and feeding related changes of NUCB2A/nesfatin-1 in Ya-fish (Schizothorax prenanti). Gene 536, 238–246 (2014). doi:10.1016/j.gene.2013.12.031 PubMedCrossRef

21.

A.G. Senejani, T.C. Gaupale, S. Unniappan, S. Bhargava, Nesfatin-1/nucleobindin-2 like immunoreactivity in the olfactory system, brain and pituitary of frog, Microhyla ornata. Gen. Comp. Endocrinol. 202, 8–14 (2014). doi:10.1016/j.ygcen.2014.04.007 PubMedCrossRef

22.

H. Shimizu, M. Mori, The brain-adipose axis: a review of involvement of molecules. Nutr. Neurosci. 8, 7–20 (2005). doi:10.1080/10284150500047245 PubMedCrossRef

23.

M. Yamada, K. Horiguchi, R. Umezawa, K. Hashimoto, T. Satoh, A. Ozawa et al., Troglitazone, a ligand of peroxisome proliferator-activated receptor-{gamma}, stabilizes NUCB2 (Nesfatin) mRNA by activating the ERK1/2 pathway: isolation and characterization of the human NUCB2 gene. Endocrinology 151, 2494–2503 (2010). doi:10.1210/en.2009-1169 PubMedCrossRef

24.

T.O. Price, W.K. Samson, M.L. Niehoff, W.A. Banks, Permeability of the blood-brain barrier to a novel satiety molecule nesfatin-1. Peptides 28, 2372–2381 (2007). doi:10.1016/j.peptides.2007.10.008 PubMedCrossRef

25.

W. Pan, H. Hsuchou, A.J. Kastin, Nesfatin-1 crosses the blood-brain barrier without saturation. Peptides 28, 2223–2228 (2007). doi:10.1016/j.peptides.2007.09.005 PubMedCrossRef

26.

H. Shimizu, S. Oh-I, K. Hashimoto, M. Nakata, S. Yamamoto, N. Yoshida et al., Peripheral administration of nesfatin-1 reduces food intake in mice: the leptin-independent mechanism. Endocrinology 150, 662–671 (2009). doi:10.1210/en.2008-0598 PubMedCrossRef

27.

A. Stengel, M. Goebel, L. Wang, J. Rivier, P. Kobelt, H. Mönnikes et al., Central nesfatin-1 reduces dark-phase food intake and gastric emptying in rats: differential role of corticotropin-releasing factor2 receptor. Endocrinology 150, 4911–4919 (2009). doi:10.1210/en.2009-0578 PubMedPubMedCentralCrossRef

28.

K. Atsuchi, A. Asakawa, M. Ushikai, K. Ataka, M. Tsai, K. Koyama et al., Centrally administered nesfatin-1 inhibits feeding behaviour and gastroduodenal motility in mice. NeuroReport 21, 1008–1011 (2010). doi:10.1097/WNR.0b013e32833f7b96 PubMed

29.

S. Unniappan, R. Gonzalez, R.L.S. Perry, X. Gao, M.P. Gaidhu, R.G. Tsushima et al., Nutrient responsive nesfatin-1 regulates energy balance and induces glucose-stimulated insulin secretion in rats. Endocrinology 152, 3628–3637 (2011). doi:10.1210/en.2010-1471 PubMedCrossRef

30.

S. Mortazavi, R. Gonzalez, R. Ceddia, S. Unniappan, Long-term infusion of nesfatin-1 causes a sustained regulation of whole-body energy homeostasis of male Fischer 344 rats. Front. Cell Dev. Biol. 3, 1–12 (2015). doi:10.3389/fcell.2015.00022 CrossRef

31.

H. Mohan, S. Unniappan, Ontogenic pattern of nucleobindin-2/nesfatin-1 expression in the gastroenteropancreatic tissues and serum of Sprague Dawley rats. Regul. Pept. 175, 61–69 (2012). doi:10.1016/j.regpep.2012.02.006 PubMedCrossRef

32.

Q.-C. Li, H.-Y. Wang, X. Chen, H.-Z. Guan, Z.-Y. Jiang, Fasting plasma levels of nesfatin-1 in patients with type 1 and type 2 diabetes mellitus and the nutrient-related fluctuation of nesfatin-1 level in normal humans. Regul. Pept. 159, 72–77 (2010). doi:10.1016/j.regpep.2009.11.003 PubMedCrossRef

33.

B.K. Tan, M. Hallschmid, W. Kern, H. Lehnert, H.S. Randeva, Decreased cerebrospinal fluid/plasma ratio of the novel satiety molecule, nesfatin-1/NUCB-2, in obese humans : evidence of nesfatin-1/NUCB-2 resistance and implications for obesity treatment. J. Clin. Endocrinol. Metab. 96, E669–E673 (2011). doi:10.1210/jc.2010-1782 PubMedCrossRef

34.

L. Jiang, J. Bao, X. Zhou, Y. Xiong, L. Wu, Increased serum levels and chondrocyte expression of nesfatin-1 in patients with osteoarthritis and its relation with BMI, hsCRP, and IL-18. Mediators Inflamm. 2013, 631251 (2013). doi:10.1155/2013/631251 PubMedPubMedCentral

35.

S. Aydin, E. Dag, Y. Ozkan, F. Erman, A.F. Dagli, N. Kilic et al., Nesfatin-1 and ghrelin levels in serum and saliva of epileptic patients: hormonal changes can have a major effect on seizure disorders. Mol. Cell. Biochem. 328, 49–56 (2009). doi:10.1007/s11010-009-0073-x PubMedCrossRef

36.

S. Aydin, The presence of the peptides apelin, ghrelin and nesfatin-1 in the human breast milk, and the lowering of their levels in patients with gestational diabetes mellitus. Peptides 31, 2236–2240 (2010). doi:10.1016/j.peptides.2010.08.021 PubMedCrossRef

37.

M. Ramanjaneya, J. Chen, J.E. Brown, G. Tripathi, M. Hallschmid, S. Patel et al., Identification of nesfatin-1 in human and murine adipose tissue: a novel depot-specific adipokine with increased levels in obesity. Endocrinology 151, 3169–3180 (2010). doi:10.1210/en.2009-1358 PubMedCrossRef

38.

A. Stengel, M. Goebel, I. Yakubov, L. Wang, D. Witcher, T. Coskun et al., Identification and characterization of nesfatin-1 immunoreactivity in endocrine cell types of the rat gastric oxyntic mucosa. Endocrinology 150, 232–238 (2009). doi:10.1210/en.2008-0747 PubMedPubMedCentralCrossRef

39.

R. Gonzalez, A. Tiwari, S. Unniappan, Pancreatic beta cells colocalize insulin and pronesfatin immunoreactivity in rodents. Biochem. Biophys. Res. Commun. 381, 643–648 (2009). doi:10.1016/j.bbrc.2009.02.104 PubMedCrossRef

40.

A.-Q. Zhang, Expression of nesfatin-1/NUCB2 in rodent digestive system. World J. Gastroenterol. 16, 1735–1741 (2010). doi:10.3748/wjg.v16.i14.1735 PubMedPubMedCentralCrossRef

41.

D. García-Galiano, R. Pineda, T. Ilhan, J.M. Castellano, F. Ruiz-Pino, M.A. Sánchez-Garrido et al., Cellular distribution, regulated expression, and functional role of the anorexigenic peptide, NUCB2/nesfatin-1, in the testis. Endocrinology 153, 1959–1971 (2012). doi:10.1210/en.2011-2032 PubMedCrossRef

42.

J. Kim, Y. Chung, H. Kim, E. Im, H. Lee, H. Yang, The tissue distribution of nesfatin-1/NUCB2 in mouse. Balsaeng’gwa Saengsig. 18, 301–309 (2014). doi:10.12717/devrep.2014.18.4.301

43.

T. Angelone, E. Filice, T. Pasqua, N. Amodio, M. Galluccio, G. Montesanti et al., Nesfatin-1 as a novel cardiac peptide: identification, functional characterization, and protection against ischemia/reperfusion injury. Cell. Mol. Life Sci. 70, 495–509 (2013). doi:10.1007/s00018-012-1138-7 PubMedCrossRef

44.

S. Feijóo-Bandín, D. Rodríguez-Penas, V. García-Rúa, A. Mosquera-Leal, M.F. Otero, E. Pereira et al., Nesfatin-1 in human and murine cardiomyocytes: synthesis, secretion, and mobilization of GLUT-4. Endocrinology 154, 4757–4767 (2013). doi:10.1210/en.2013-1497 PubMedCrossRef

45.

S. Gonkowski, A. Rychlik, M. Nowicki, R. Nieradka, M. Bulc, J. Całka, A population of nesfatin 1-like immunoreactive (LI) cells in the mucosal layer of the canine digestive tract. Res. Vet. Sci. 93, 1119–1121 (2012). doi:10.1016/j.rvsc.2012.06.002 PubMedCrossRef

46.

C.A. Lents, C.R. Barb, G.J. Hausman, D. Nonneman, N.L. Heidorn, R.S. Cisse et al., Effects of nesfatin-1 on food intake and LH secretion in prepubertal gilts and genomic association of the porcine NUCB2 gene with growth traits. Domest. Anim. Endocrinol. 45, 89–97 (2013). doi:10.1016/j.domaniend.2013.06.002 PubMedCrossRef

47.

E. Varricchio, M.G. Russolillo, F. Russo, V. Lombardi, M. Paolucci, L. Maruccio, Expression and immunohistochemical detection of nesfatin-1 in the gastrointestinal tract of Casertana pig. Acta Histochem. 116, 583–587 (2014). doi:10.1016/j.acthis.2013.11.006 PubMedCrossRef

48.

S. Aydin, Presence of adropin, nesfatin-1, apelin-12, ghrelins and salusins peptides in the milk, cheese whey and plasma of dairy cows. Peptides 43, 83–87 (2013). doi:10.1016/j.peptides.2013.02.014 PubMedCrossRef

49.

R. Gonzalez, E. Shepperd, V. Thiruppugazh, S. Lohan, C.L. Grey, J.P. Chang et al., Nesfatin-1 regulates the hypothalamo-pituitary-ovarian axis of fish. Biol. Reprod. 87, 84 (2012). doi:10.1095/biolreprod.112.099630 PubMedCrossRef

50.

B. Kerbel, S. Unniappan, Nesfatin-1 suppresses energy intake, co-localises ghrelin in the brain and gut, and alters ghrelin, cholecystokinin and orexin mRNA expression in goldfish. J. Neuroendocrinol. 24, 366–377 (2012). doi:10.1111/j.1365-2826.2011.02246.x PubMedCrossRef

51.

L.K. Caldwell, A.L. Pierce, L.G. Riley, C.A. Duncan, J.J. Nagler, Plasma nesfatin-1 is not affected by long-term food restriction and does not predict rematuration among iteroparous female rainbow trout (oncorhynchus mykiss). PLoS One 9, e85700 (2014). doi:10.1371/journal.pone.0085700 PubMedPubMedCentralCrossRef

52.

A. Stengel, Nesfatin-1 – More than a food intake regulatory peptide. Peptides, 1–9 (2015). doi:10.1016/j.peptides.2015.06.002

53.

S. Aydin, Multi-functional peptide hormone NUCB2/nesfatin-1. Endocrine 44, 312–325 (2013). doi:10.1007/s12020-013-9923-0 PubMedCrossRef

54.

C. Ayada, Ü. Toru, Y. Korkut, Nesfatin-1 and its effects on different systems. Hippokratia 19(1), 4–10 (2015). http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4574585&tool=pmcentrez&rendertype=abstract

55.

A. Stengel, M. Goebel-stengel, L. Wang, I. Kato, M. Mori, Y. Taché, Nesfatin-130–59 but not the N- and C-terminal fragments, nesfatin-11–29 and nesfatin-160–82 injected intracerebroventricularly decreases dark phase food intake by increasing inter-meal intervals in mice. Peptides 35, 2–7 (2012). doi:10.1016/j.peptides.2012.03.015 CrossRef

56.

E. Ishida, K. Hashimoto, H. Shimizu, S. Okada, T. Satoh, I. Kato et al., Nesfatin-1 induces the phosphorylation levels of cAMP response element-binding protein for intracellular signaling in a neural cell line. PLoS One 7, e50918 (2012). doi:10.1371/journal.pone.0050918 PubMedPubMedCentralCrossRef

57.

H. Shimizu, S. Oh-I, S. Okada, M. Mori, Nesfatin-1: an overview and future clinical application. Endocr. J. 56, 537–543 (2009). http://joi.jlc.jst.go.jp/JST.JSTAGE/endocrj/K09E−117?from=CrossRef

58.

Y. Tagaya, A. Miura, S. Okada, K. Ohshima, M. Mori, Nucleobindin-2 is a positive modulator of EGF-dependent signals leading to enhancement of cell growth and suppression of adipocyte differentiation. Endocrinology 153, 3308–3319 (2012). doi:10.1210/en.2011-2154 PubMedCrossRef

59.

M. Ramanjaneya, M. Addison, H. S Randeva, Possible Role of NUCB2/nesfatin-1 in Adipogenesis. Curr. Pharm. Des. 19(39), 6976–6980 (2013)PubMedCrossRef

60.

M.K. Piya, P.G. McTernan, S. Kumar, Adipokine inflammation and insulin resistance: the role of glucose, lipids and endotoxin. J. Endocrinol. 216, T1–T15 (2013). doi:10.1530/JOE-12-0498 PubMedCrossRef

61.

R. Gonzalez, B.K. Reingold, X. Gao, M.P. Gaidhu, R.G. Tsushima, S. Unniappan, Nesfatin-1 exerts a direct, glucose-dependent insulinotropic action on mouse islet β- and MIN6 cells. J. Endocrinol. 208, R9–R16 (2011). doi:10.1530/JOE-10-0492 PubMed

62.

K.S. Foo, H. Brauner, C.-G. Ostenson, C. Broberger, Nucleobindin-2/nesfatin in the endocrine pancreas: distribution and relationship to glycaemic state. J. Endocrinol. 204, 255–263 (2010). doi:10.1677/JOE-09-0254 PubMedCrossRef

63.

Y. Su, J. Zhang, Y. Tang, F. Bi, J.-N. Liu, The novel function of nesfatin-1: anti-hyperglycemia. Biochem. Biophys. Res. Commun. 391, 1039–1042 (2010). doi:10.1016/j.bbrc.2009.12.014 PubMedCrossRef

64.

Z. Li, L. Gao, H. Tang, Y. Yin, X. Xiang, Y. Li et al., Peripheral effects of nesfatin-1 on glucose homeostasis. PLoS One 8, e71513 (2013). doi:10.1371/journal.pone.0071513 PubMedPubMedCentralCrossRef

65.

J. Dong, H. Xu, P.-F. Wang, G.-J. Cai, H.-F. Song, C.-C. Wang et al., Nesfatin-1 stimulates fatty-acid oxidation by activating AMP-activated protein kinase in STZ-induced type 2 diabetic mice. PLoS One 8, e83397 (2013). doi:10.1371/journal.pone.0083397 PubMedPubMedCentralCrossRef

66.

X. Chen, J. Dong, Z.-Y. Jiang, Nesfatin-1 influences the excitability of glucosensing neurons in the hypothalamic nuclei and inhibits the food intake. Regul. Pept. 177, 21–26 (2012). doi:10.1016/j.regpep.2012.04.003 PubMedCrossRef

67.

J. Dong, H.-Z. Guan, Z.-Y. Jiang, X. Chen, Nesfatin-1 influences the excitability of glucosensing neurons in the dorsal vagal complex and inhibits food intake. PLoS One 9, e98967 (2014). doi:10.1371/journal.pone.0098967 PubMedPubMedCentralCrossRef

68.

M.S. Bonnet, M. Djelloul, V. Tillement, C. Tardivel, L. Mounien, J. Trouslard et al., Central NUCB2/nesfatin-1-expressing neurones belong to the hypothalamic-brainstem circuitry activated by hypoglycaemia. J. Neuroendocrinol. 25, 1–13 (2013). doi:10.1111/j.1365-2826.2012.02375.x PubMedCrossRef

69.

D. Gantulga, Y. Maejima, M. Nakata, T. Yada, Glucose and insulin induce Ca2 + signaling in nesfatin-1 neurons in the hypothalamic paraventricular nucleus. Biochem. Biophys. Res. Commun. 420, 811–815 (2012). doi:10.1016/j.bbrc.2012.03.079 PubMedCrossRef

70.

D. Wu, M. Yang, Y. Chen, Y. Jia, Z.A. Ma, G. Boden et al., Hypothalamic nesfatin-1/NUCB2 knockdown augments hepatic gluconeogenesis that is correlated with inhibition of mTOR-STAT3 signaling pathway in rats. Diabetes 63, 1234–1247 (2014). doi:10.2337/db13-0899 PubMedCrossRef

71.

K. Könczöl, O. Pintér, S. Ferenczi, J. Varga, K. Kovács, M. Palkovits et al., Nesfatin-1 exerts long-term effect on food intake and body temperature. Int. J. Obes. (Lond) 36, 1514–1521 (2012). doi:10.1038/ijo.2012.2 CrossRef

72.

O. Başar, E. Akbal, S. Köklü, E. Koçak, Y. Tuna, F. Ekiz et al., A novel appetite peptide, nesfatin-1 in patients with non-alcoholic fatty liver disease. Scand. J. Clin. Lab. Invest. 72, 479–483 (2012). doi:10.3109/00365513.2012.699097 PubMedCrossRef

73.

A. Abaci, G. Catli, A. Anik, T. Kume, E. Bober, The relation of serum nesfatin-1 level with metabolic and clinical parameters in obese and healthy children. Pediatr. Diabetes. 14, 189–195 (2013). doi:10.1111/pedi.12009 PubMed

74.

T. Tsuchiya, H. Shimizu, M. Yamada, A. Osaki, S. Oh-I, Y. Ariyama et al., Fasting concentrations of nesfatin-1 are negatively correlated with body mass index in non-obese males. Clin. Endocrinol. (Oxf) 73, 484–490 (2010). doi:10.1111/j.1365-2265.2010.03835.x

75.

K. Ogiso, A. Asakawa, H. Amitani, T. Nakahara, M. Ushikai, I. Haruta et al., Plasma nesfatin-1 concentrations in restricting-type anorexia nervosa. Peptides 32, 150–153 (2011). doi:10.1016/j.peptides.2010.10.004 PubMedCrossRef

76.

Y. Ozkan, E.S. Timurkan, S. Aydin, I. Sahin, M. Timurkan, C. Citil et al., Acylated and desacylated ghrelin, preptin, leptin, and nesfatin-1 Peptide changes related to the body mass index. Int. J. Endocrinol. 2013, 236085 (2013). doi:10.1155/2013/236085 PubMedPubMedCentralCrossRef

77.

J.F. Saldanha, J.J. Carrero, J.C. Lobo, M.B. Stockler-Pinto, V.O. Leal, A. Calixto et al., The newly identified anorexigenic adipokine nesfatin-1 in hemodialysis patients: Are there associations with food intake, body composition and inflammation? Regul. Pept. 173, 82–85 (2012). doi:10.1016/j.regpep.2011.09.010 PubMedCrossRef

78.

G.M. Anwar, G. Yamamah, A. Ibrahim, D. El-Lebedy, T.M. Farid, R. Mahmoud, Nesfatin-1 in childhood and adolescent obesity and its association with food intake, body composition and insulin resistance. Regul. Pept. 188, 21–24 (2014). doi:10.1016/j.regpep.2013.12.001 PubMedCrossRef

79.

F. Liu, Q. Yang, N. Gao, F. Liu, S. Chen, Decreased plasma nesfatin-1 level is related to the thyroid dysfunction in patients with type 2 diabetes mellitus. J Diabetes Res. 2014, 128014 (2014). doi:10.1155/2014/128014 PubMedPubMedCentral

80.

Y. Zhao, X. Ma, Q. Wang, Y. Zhou, Y. Zhang, L. Wu et al., Nesfatin-1 correlates with hypertension in overweight or obese Han Chinese population. Clin. Exp. Hypertens. 1963, 1–6 (2014). doi:10.3109/10641963.2014.897722

81.

M. Aslan, O. Celik, N. Celik, I. Turkcuoglu, E. Yilmaz, A. Karaer et al., Cord blood nesfatin-1 and apelin-36 levels in gestational diabetes mellitus. Endocrine 41, 424–429 (2012). doi:10.1007/s12020-011-9577-8 PubMedCrossRef

82.

Z. Zhang, L. Li, M. Yang, H. Liu, G. Boden, G. Yang, Increased plasma levels of nesfatin-1 in patients with newly diagnosed type 2 diabetes mellitus. Exp. Clin. Endocrinol. Diabetes 120, 91–95 (2012). doi:10.1055/s-0031-1286339 PubMedCrossRef

83.

Z.-F. Xia, D.M. Fritze, J.-Y. Li, B. Chai, C. Zhang, W. Zhang et al., Nesfatin-1 inhibits gastric acid secretion via a central vagal mechanism in rats. Am. J. Physiol. Gastrointest. Liver Physiol. 303, G570–G577 (2012). doi:10.1152/ajpgi.00178.2012 PubMedPubMedCentralCrossRef

84.

A. Szlachcic, Z. Sliwowski, G. Krzysiek-Maczka, J. Majka, M. Surmiak, R. Pajdo et al., New satiety hormone nesfatin-1 protects gastric mucosa against stress-induced injury: mechanistic roles of prostaglandins, nitric oxide, sensory nerves and vanilloid receptors. Peptides 49C, 9–20 (2013). doi:10.1016/j.peptides.2013.07.017 CrossRef

85.

M. Kolgazi, C. Cantali-Ozturk, R. Deniz, Z.N. Ozdemir-Kumral, M. Yuksel, S. Sirvanci et al., Nesfatin-1 alleviates gastric damage via direct antioxidant mechanisms. J. Surg. Res. (2014). doi:10.1016/j.jss.2014.06.057 PubMed

86.

Z.-L. Li, L. Xu, X.-R. Sun, F.-F. Guo, Y.-L. Gong, S.-L. Gao, Central nesfatin-1 influences the excitability of ghrelin-responsive gastric distension neurons in the arcuate nucleus and reduces gastric motility in rats. Eur. J. Neurosci. 38, 3636–3643 (2013). doi:10.1111/ejn.12366 PubMedCrossRef

87.

S.L. Chagra, J.K. Zavala, M.V. Hall, K.L. Gosselink, Acute and repeated restraint differentially activate orexigenic pathways in the rat hypothalamus. Regul. Pept. 167, 70–78 (2011). doi:10.1016/j.regpep.2010.11.006 PubMedPubMedCentralCrossRef

88.

K.M. Carlin, W.W. Vale, T.L. Bale, Vital functions of corticotropin-releasing factor (CRF) pathways in maintenance and regulation of energy homeostasis. Proc. Natl. Acad. Sci. USA 103, 3462–3467 (2006). doi:10.1073/pnas.0511320103 PubMedPubMedCentralCrossRef

89.

K.S. Foo, H. Brismar, C. Broberger, Distribution and neuropeptide coexistence of nucleobindin-2 mRNA/nesfatin-like immunoreactivity in the rat CNS. Neuroscience 156, 563–579 (2008). doi:10.1016/j.neuroscience.2008.07.054 PubMedCrossRef

90.

M. Goebel, A. Stengel, L. Wang, N.W.G. Lambrecht, Y. Taché, Nesfatin-1 immunoreactivity in rat brain and spinal cord autonomic nuclei. Neurosci. Lett. 452, 241–246 (2009). doi:10.1016/j.neulet.2009.01.064 PubMedPubMedCentralCrossRef

91.

M. Goebel, A. Stengel, L. Wang, Y. Taché, Restraint stress activates nesfatin-1-immunoreactive brain nuclei in rats. Brain Res. 1300, 114–124 (2009). doi:10.1016/j.brainres.2009.08.082 PubMedPubMedCentralCrossRef

92.

L. Xu, B. Bloem, B. Gaszner, E.W. Roubos, T. Kozicz, Stress-related changes in the activity of cocaine- and amphetamine-regulated transcript and nesfatin neurons in the midbrain non-preganglionic Edinger-Westphal nucleus in the rat. Neuroscience 170, 478–488 (2010). doi:10.1016/j.neuroscience.2010.07.001 PubMedCrossRef

93.

Y. Taché, B. Bonaz, Corticotropin-releasing factor receptors and stress-related alterations of gut motor function. J. Clin. Invest. 117, 33–40 (2007). doi:10.1172/JCI30085 PubMedPubMedCentralCrossRef

94.

Z. Merali, C. Cayer, P. Kent, H. Anisman, Nesfatin-1 increases anxiety- and fear-related behaviors in the rat. Psychopharmacology 201, 115–123 (2008). doi:10.1007/s00213-008-1252-2 PubMedCrossRef

95.

T. Hofmann, A. Stengel, A. Ahnis, P. Buße, U. Elbelt, B.F. Klapp, NUCB2/nesfatin-1 is associated with elevated scores of anxiety in female obese patients. Psychoneuroendocrinology 38, 2502–2510 (2013). doi:10.1016/j.psyneuen.2013.05.013 PubMedCrossRef

96.

T. Hofmann, A. Ahnis, U. Elbelt, M. Rose, B.F. Klapp, A. Stengel, NUCB2/nesfatin-1 is associated with elevated levels of anxiety in anorexia nervosa. PLoS One 10, e0132058 (2015). doi:10.1371/journal.pone.0132058 PubMedPubMedCentralCrossRef

97.

T. Hofmann, U. Elbelt, A. Ahnis, M. Rose, B.F. Klapp, A. Stengel, Sex-specific regulation of NUCB2/nesfatin-1: differential implication in anxiety in obese men and women. Psychoneuroendocrinology 60, 130–137 (2015). doi:10.1016/j.psyneuen.2015.06.014 PubMedCrossRef

98.

S. Jego, D. Salvert, L. Renouard, M. Mori, R. Goutagny, P.-H. Luppi et al., Tuberal hypothalamic neurons secreting the satiety molecule Nesfatin-1 are critically involved in paradoxical (REM) sleep homeostasis. PLoS One 7, e52525 (2012). doi:10.1371/journal.pone.0052525 PubMedPubMedCentralCrossRef

99.

S. Vas, C. Adori, K. Könczöl, Z. Kátai, D. Pap, R.S. Papp et al., Nesfatin-1/NUCB2 as a potential new element of sleep regulation in rats. PLoS ONE 8, e59809 (2013). doi:10.1371/journal.pone.0059809 PubMedPubMedCentralCrossRef

100.

D. García-Galiano, V.M. Navarro, J. Roa, F. Ruiz-Pino, M.A. Sánchez-Garrido, R. Pineda et al., The anorexigenic neuropeptide, nesfatin-1, is indispensable for normal puberty onset in the female rat. J. Neurosci. 30, 7783–7792 (2010). doi:10.1523/JNEUROSCI.5828-09.2010 PubMedCrossRef

101.

R. Deniz, B. Gurates, S. Aydin, H. Celik, Iİ. Sahin, Y. Baykus et al., Nesfatin-1 and other hormone alterations in polycystic ovary syndrome. Endocrine 42, 694–699 (2012). doi:10.1007/s12020-012-9638-7 PubMedCrossRef

102.

T. Boutsikou, D.D. Briana, M. Boutsikou, G. Kafalidis, D. Piatopoulou, S. Baka et al., Cord blood nesfatin-1 in large for gestational age pregnancies. Cytokine 61, 591–594 (2013). doi:10.1016/j.cyto.2012.10.029 PubMedCrossRef

103.

D. García-Galiano, V.M. Navarro, F. Gaytan, M. Tena-Sempere, Expanding roles of NUCB2/nesfatin-1 in neuroendocrine regulation. J. Mol. Endocrinol. 45, 281–290 (2010). doi:10.1677/JME-10-0059 PubMedCrossRef

104.

G. Çatlı, a. Anık, T. Küme, Ö.G. Çalan, B.N. Dündar, E. Böber, et al., Serum nesfatin-1 and leptin levels in non-obese girls with premature thelarche. J. Endocrinol. Invest. (2015). doi:10.1007/s40618-015-0277-8

105.

E.N. Ademoglu, S. Gorar, A. Carlıoglu, H. Yazıcı, F.D. Dellal, Z. Berberoglu et al., Plasma nesfatin-1 levels are increased in patients with polycystic ovary syndrome. J. Endocrinol. Invest. (2014). doi:10.1007/s40618-014-0089-2 PubMed

106.

T. Kawabe, K. Kawabe, H.N. Sapru, Cardiovascular responses to chemical stimulation of the hypothalamic arcuate nucleus in the rat: role of the hypothalamic paraventricular nucleus. PLoS One 7, e45180 (2012). doi:10.1371/journal.pone.0045180 PubMedPubMedCentralCrossRef

107.

B. Erdos, R.R. Clifton, M. Liu, H. Li, M.L. McCowan, C. Sumners, D.A. Scheuer, Novel mechanism within the paraventricular nucleus reduces both blood pressure and hypothalamic pituitary-adrenal axis responses to acute stress. Am. J. Physiol. Heart Circ. Physiol. 309(4), H634–H645 (2015). doi:10.1152/ajpheart.00207.2015 PubMedCrossRef

108.

G.P. Pajolla, F.M. de Aguiar Corrêa, Cardiovascular responses to the injection of L-glutamate in the lateral hypothalamus of unanesthetized or anesthetized rats. Auton. Neurosci. 116, 19–29 (2004). doi:10.1016/j.autneu.2004.08.010 PubMedCrossRef

109.

N. Japundžić-Žigon, Vasopressin and oxytocin in control of the cardiovascular system. Curr. Neuropharmacol. 11, 218–230 (2013). doi:10.2174/1570159X11311020008 PubMedPubMedCentralCrossRef

110.

A. Machhada, R. Ang, G.L. Ackland, N. Ninkina, V.L. Buchman, M.F. Lythgoe et al., Control of ventricular excitability by neurons of the dorsal motor nucleus of the vagus nerve. Heart Rhythm. (2015). doi:10.1016/j.hrthm.2015.06.005 PubMedPubMedCentral

111.

É.M. Granjeiro, S.S. Marroni, D.P. Martins Dias, L.G. Heck Bonagamba, K.M. Costa, J.C. dos Santos et al., Behavioral and cardiorespiratory responses to bilateral microinjections of oxytocin into the central nucleus of amygdala of Wistar rats, an experimental model of compulsion. PLoS One 9, e99284 (2014). doi:10.1371/journal.pone.0099284 PubMedPubMedCentralCrossRef

112.

M. Nagai, S. Hoshide, K. Kario, The insular cortex and cardiovascular system: a new insight into the brain-heart axis. J. Am. Soc. Hypertens. 4, 174–182 (2010). doi:10.1016/j.jash.2010.05.001 PubMedCrossRef

113.

D.B. Sharp, X. Wang, D. Mendelowitz, Dexmedetomidine decreases inhibitory but not excitatory neurotransmission to cardiac vagal neurons in the nucleus ambiguus. Brain Res. 1574, 1–5 (2014). doi:10.1016/j.brainres.2014.06.010 PubMedPubMedCentralCrossRef

114.

J. Bundzikova-Osacka, S. Ghosal, B.A. Packard, Y.M. Ulrich-Lai, J.P. Herman, Role of nucleus of the solitary tract noradrenergic neurons in post-stress cardiovascular and hormonal control in male rats. Stress 18, 221–232 (2015). doi:10.3109/10253890.2015.1013531 PubMedPubMedCentralCrossRef

115.

G.L.C. Yosten, W.K. Samson, Nesfatin-1 exerts cardiovascular actions in brain: possible interaction with the central melanocortin system. Am. J. Physiol. Regul. Integr. Comp. Physiol. 297, R330–R336 (2009). doi:10.1152/ajpregu.90867.2008 PubMedPubMedCentralCrossRef

116.

K. Matsumura, T. Tsuchihashi, I. Abe, M. Iida, Central alpha-melanocyte-stimulating hormone acts at melanocortin-4 receptor to activate sympathetic nervous system in conscious rabbits. Brain Res. 948, 145–8 (2002). http://www.ncbi.nlm.nih.gov/pubmed/12383966. Accessed 14 Nov 2013

117.

D. Ramaekers, F. Beckers, H. Demeulemeester, C. Bert, C. Denef, A.E. Aubert, Effects of melanocortins on cardiovascular regulation in rats. Clin. Exp. Pharmacol. Physiol. 29, 549–58 (2002). http://www.ncbi.nlm.nih.gov/pubmed/12060096. Accessed 14 Nov 2013

118.

N. Sabatier, C. Caquineau, A.J. Douglas, G. Leng, Oxytocin released from magnocellular dendrites: a potential modulator of alpha-melanocyte-stimulating hormone behavioral actions? Ann. N. Y. Acad. Sci. 994, 218–224 (2003)PubMedCrossRef

119.

L.C. Michelini, M.C. Marcelo, J. Amico, M. Morris, Oxytocinergic regulation of cardiovascular function: studies in oxytocin-deficient mice. Am. J. Physiol. Heart Circ. Physiol. 284, H2269–H2276 (2003). doi:10.1152/ajpheart.00774.2002 PubMedCrossRef

120.

A. Mimee, P.M. Smith, A.V. Ferguson, Nesfatin-1 influences the excitability of neurons in the nucleus of the solitary tract and regulates cardiovascular function. Am. J. Physiol. Regul. Integr. Comp. Physiol. 302, R1297–R1304 (2012). doi:10.1152/ajpregu.00266.2011 PubMedCrossRef

121.

G.L.C. Yosten, W.K. Samson, The anorexigenic and hypertensive effects of nesfatin-1 are reversed by pretreatment with an oxytocin receptor antagonist. Am. J. Physiol. Regul. Integr. Comp. Physiol. 298, R1642–R1647 (2010). doi:10.1152/ajpregu.00804.2009 PubMedPubMedCentralCrossRef

122.

D.G. Baskin, F. Kim, R.W. Gelling, B.J. Russell, M.W. Schwartz, G.J. Morton et al., A new oxytocin-saporin cytotoxin for lesioning oxytocin-receptive neurons in the rat hindbrain. Endocrinology 151, 4207–4213 (2010). doi:10.1210/en.2010-0295 PubMedPubMedCentralCrossRef

123.

T. Kishi, C.J. Aschkenasi, C.E. Lee, K.G. Mountjoy, C.B. Saper, J.K. Elmquist, Expression of melanocortin 4 receptor mRNA in the central nervous system of the rat. J. Comp. Neurol. 457, 213–235 (2003). doi:10.1002/cne.10454 PubMedCrossRef

124.

G.C. Brailoiu, E. Deliu, A.A. Tica, J.E. Rabinowitz, D.G. Tilley, K. Benamar et al., Nesfatin-1 activates cardiac vagal neurons of nucleus ambiguus and elicits bradycardia in conscious rats. J. Neurochem. 126, 739–748 (2013). doi:10.1111/jnc.12355 PubMedPubMedCentralCrossRef

125.

A.D. de Kloet, M. Liu, V. Rodriguez, E.G. Krause, C. Sumners, Role of neurons and glia in the CNS actions of the renin-angiotensin system in cardiovascular control. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2015). doi:10.1152/ajpregu.00078.2015 PubMed

126.

M. Tanida, A. Niijima, J. Shen, S. Yamada, H. Sawai, Y. Fukuda et al., Dose-different effects of orexin-A on the renal sympathetic nerve and blood pressure in urethane-anesthetized rats. Exp. Biol. Med. (Maywood) 231, 1616–1625 (2006)

127.

M. Tanida, J. Shen, K. Nagai, Possible role of the histaminergic system in autonomic and cardiovascular responses to neuropeptide Y. Neuropeptides 43, 21–29 (2009). doi:10.1016/j.npep.2008.09.007 PubMedCrossRef

128.

M. Tanida, N. Shintani, Y. Morita, N. Tsukiyama, M. Hatanaka, H. Hashimoto et al., Regulation of autonomic nerve activities by central pituitary adenylate cyclase-activating polypeptide. Regul. Pept. 161, 73–80 (2010). doi:10.1016/j.regpep.2010.02.002 PubMedCrossRef

129.

M. Tanida, M. Mori, Nesfatin-1 stimulates renal sympathetic nerve activity in rats. NeuroReport 22, 309–312 (2011). doi:10.1097/WNR.0b013e328346107f PubMedCrossRef

130.

M.S. Yilmaz, B. Altinbas, G. Guvenc, L.G. Erkan, O. Avsar, V. Savci et al., The role of centrally injected nesfatin-1 on cardiovascular regulation in normotensive and hypotensive rats. Auton. Neurosci. (2015). doi:10.1016/j.autneu.2015.07.009

131.

M. Tanida, H. Gotoh, N. Yamamoto, M. Wang, Y. Kuda, Y. Kurata et al., Hypothalamic nesfatin-1 stimulates sympathetic nerve activity via hypothalamic ERK signaling. Diabetes (2015). doi:10.2337/db15-0282 PubMed

132.

A. Osaki, H. Shimizu, Peripheral administration of nesfatin-1 increases blood pressure in mice. Hypertens. Res. 37, 185–186 (2014). doi:10.1038/hr.2013.122 PubMedCrossRef

133.

C. Zhang, Y. Wang, Y. Wang, J. Li, R. Liu, H. Liu, Decreased levels of serum nesfatin-1 in patients with preeclampsia. Biomarkers 19, 402–406 (2014). doi:10.3109/1354750X.2014.919027 PubMedCrossRef

134.

A. Turgut, A. Ozler, N.Y. Goruk, S.Y. Tunç, M.E. Sak, M.S. Evsen, et al., Serum levels of the adipokines, free fatty acids, and oxidative stress markers in obese and non-obese preeclamptic patients. Clin. Exp. Obstet. Gynecol. 42, 473–9 (2015). http://www.ncbi.nlm.nih.gov/pubmed/26411214. Accessed 13 Oct 2015

135.

F. Kir Sahin, S. Baydur Sahin, U. Mete Ural, M. Cumhur Cure, S. Senturk, Y. Bayoglu Tekin, et al., Nesfatin-1 and Vitamin D levels may be associated with systolic and diastolic blood pressure values and hearth rate in polycystic ovary syndrome. Bosn. J. Basic Med. Sci. 15 57–63 (2015). http://www.ncbi.nlm.nih.gov/pubmed/26295295. Accessed 24 Aug 2015

136.

P.M. Spritzer, S.B. Lecke, F. Satler, D.M. Morsch, Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome. Reproduction 149, R219–R227 (2015). doi:10.1530/REP-14-0435 PubMedCrossRef

137.

I. Bernatova, Endothelial dysfunction in experimental models of arterial hypertension: cause or consequence? Biomed. Res. Int. 2014, 598271 (2014). doi:10.1155/2014/598271 PubMedPubMedCentral

138.

H. Yamawaki, M. Takahashi, M. Mukohda, T. Morita, M. Okada, Y. Hara, A novel adipocytokine, nesfatin-1 modulates peripheral arterial contractility and blood pressure in rats. Biochem. Biophys. Res. Commun. 418, 676–681 (2012). doi:10.1016/j.bbrc.2012.01.076 PubMedCrossRef

139.

N.G. Lumsden, R.S. Khambata, A.J. Hobbs, C-type natriuretic peptide (CNP): cardiovascular roles and potential as a therapeutic target. Curr. Pharm. Des. 16, 4080–4088 (2010). http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3605774&tool=pmcentrez&rendertype=abstract. Accessed 6 May 2014

140.

S. Collins, A heart-adipose tissue connection in the regulation of energy metabolism. Nat. Rev. Endocrinol. 10, 157–163 (2014). doi:10.1038/nrendo.2013.234 PubMedCrossRef

141.

G.L.C. Yosten, L. Redlinger, W.K. Samson, Evidence for a role of endogenous nesfatin-1 in the control of water drinking. J. Neuroendocrinol. 24, 1078–1084 (2012). doi:10.1111/j.1365-2826.2012.02304.x PubMedCrossRef

142.

K. Wernecke, I. Lamprecht, O. Jöhren, H. Lehnert, C. Schulz, Nesfatin-1 increases energy expenditure and reduces food intake in rats. Obesity (Silver Spring) 22, 1662–1668 (2014). doi:10.1002/oby.20736 CrossRef

143.

R. Mazza, a. Gattuso, M. Filice, P. Cantafio, M.C. Cerra, T. Angelone, et al., Nesfatin-1 as a new positive inotrope in the goldfish (Carassius auratus) heart. Gen. Comp. Endocrinol. 1–8 (2015). doi:10.1016/j.ygcen.2015.08.003

144.

S. Cappello, T. Angelone, B. Tota, P. Pagliaro, C. Penna, R. Rastaldo et al., Human recombinant chromogranin A-derived vasostatin-1 mimics preconditioning via an adenosine/nitric oxide signaling mechanism. Am. J. Physiol. Heart Circ. Physiol. 293, H719–H727 (2007). doi:10.1152/ajpheart.01352.2006 PubMedCrossRef

145.

C. Penna, G. Alloatti, M.P. Gallo, M.C. Cerra, R. Levi, F. Tullio et al., Catestatin improves post-ischemic left ventricular function and decreases ischemia/reperfusion injury in heart. Cell. Mol. Neurobiol. 30, 1171–1179 (2010). doi:10.1007/s10571-010-9598-5 PubMedPubMedCentralCrossRef

146.

P. Pagliaro, F. Moro, F. Tullio, M.-G. Perrelli, C. Penna, Cardioprotective pathways during reperfusion: focus on redox signaling and other modalities of cell signaling. Antioxid. Redox Signal. 14, 833–850 (2011). doi:10.1089/ars.2010.3245 PubMedCrossRef

147.

D.J. Hausenloy, S. Lecour, D.M. Yellon, Reperfusion injury salvage kinase and survivor activating factor enhancement prosurvival signaling pathways in ischemic postconditioning: two sides of the same coin. Antioxid. Redox Signal. 14, 893–907 (2011). doi:10.1089/ars.2010.3360 PubMedCrossRef

148.

P. Mesirca, A.G. Torrente, M.E. Mangoni, Functional role of voltage gated Ca(2+) channels in heart automaticity. Front. Physiol. 6, 19 (2015). doi:10.3389/fphys.2015.00019 PubMedPubMedCentralCrossRef

149.

C. Ayada, G. Turgut, S. Turgut, The effect of Nesfatin-1 on heart L-type Ca²⁺ channel α1c subunit in rats subjected to chronic restraint stress. Bratisl. Lek. Listy. 116, 326–9 (2015). http://www.ncbi.nlm.nih.gov/pubmed/25924643 Accessed 27 July 2015

150.

J. Ying, Y. Zhang, S. Gong, Z. Chang, X. Zhou, H. Li et al., Nesfatin-1 Suppresses Cardiac L-type Ca²⁺ Channels Through Melanocortin Type 4 Receptor and the Novel Protein Kinase C Theta Isoform Pathway. Cell. Physiol. Biochem. 36, 555–568 (2015). doi:10.1159/000430120 PubMedCrossRef

151.

Y. Iwasaki, H. Nakabayashi, M. Kakei, H. Shimizu, M. Mori, T. Yada, Nesfatin-1 evokes Ca2+ signaling in isolated vagal afferent neurons via Ca2+ influx through N-type channels. Biochem. Biophys. Res. Commun. 390, 958–962 (2009). doi:10.1016/j.bbrc.2009.10.085 PubMedCrossRef

152.

M. Nakata, K. Manaka, S. Yamamoto, M. Mori, T. Yada, Nesfatin-1 enhances glucose-induced insulin secretion by promoting Ca(2+) influx through L-type channels in mouse islet β-cells. Endocr. J. 58, 305–313 (2011). doi:10.1507/endocrj PubMedCrossRef

153.

Y. Maejima, U. Sedbazar, S. Suyama, D. Kohno, T. Onaka, E. Takano et al., Nesfatin-1-regulated oxytocinergic signaling in the paraventricular nucleus causes anorexia through a leptin-independent melanocortin pathway. Cell Metab. 10, 355–365 (2009). doi:10.1016/j.cmet.2009.09.002 PubMedCrossRef

154.

O. Yasuda, K. Fukuo, X. Sun, M. Nishitani, T. Yotsui, M. Higuchi et al., Apop-1, a novel protein inducing cyclophilin D-dependent but Bax/Bak-related channel-independent apoptosis. J. Biol. Chem. 281, 23899–23907 (2006). doi:10.1074/jbc.M512610200 PubMedCrossRef

155.

S. Feijóo-Bandín, D. Rodríguez-Penas, V. García-Rúa, A. Mosquera-Leal, E. Abu-Assi, M. Portolés et al., 24 h nesfatin-1 treatment promotes apoptosis in cardiomyocytes. Endocrine (2015). doi:10.1007/s12020-015-0648-0

156.

H. Dai, X. Li, T. He, Y. Wang, Z. Wang, S. Wang et al., Decreased plasma nesfatin-1 levels in patients with acute myocardial infarction. Peptides 46C, 167–171 (2013). doi:10.1016/j.peptides.2013.06.006 CrossRef

157.

A. Celik, M. Gurger, Ç. Can, M. Balin, E. Gul, M.A. Kobat et al., The effect of nesfatin-1 levels on paroxysmal supraventricular tachycardia. J. Investig. Med. 61, 852–855 (2013). doi:10.231/JIM.0b013e31828dedd2 PubMed

158.

J. Wang, Serum nesfatin-1 is reduced in type 2 diabetes mellitus patients with peripheral arterial disease. Med. Sci. Monit. 21, 987–991 (2015). doi:10.12659/MSM.892611 PubMedPubMedCentralCrossRef

159.

M. Ari, O.H. Ozturk, Y. Bez, S. Oktar, D. Erduran, High plasma nesfatin-1 level in patients with major depressive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 497–500 (2011). doi:10.1016/j.pnpbp.2010.12.004 PubMedCrossRef

160.

P. Shen, Y. Han, B. Cai, Y. Wang, Decreased levels of serum nesfatin-1 in patients with obstructive sleep apnea syndrome. Sleep Breath. (2014). doi:10.1007/s11325-014-1039-0 PubMed

161.

G. Wang, Serum and synovial fluid nesfatin-1 concentration is associated with radiographic severity of knee osteoarthritis. Med. Sci. Monit. 21, 1078–1082 (2015). doi:10.12659/MSM.892875 PubMedPubMedCentralCrossRef

162.

M. Scotece, J. Conde, V. Abella, V. López, F. Lago, J. Pino et al., NUCB2/nesfatin-1: a new adipokine expressed in human and murine chondrocytes with pro-inflammatory properties, an in vitro study. J. Orthop. Res. 32, 653–660 (2014). doi:10.1002/jor.22585 PubMedCrossRef

163.

N. Gonçalves, I. Falcão-Pires, A.F. Leite-Moreira, Adipokines and their receptors: potential new targets in cardiovascular diseases. Future Med. Chem. 7, 139–157 (2015). doi:10.4155/fmc.14.147 PubMedCrossRef

164.

V. de Oliveira Leal, D. Mafra, Adipokines in obesity. Clin. Chim. Acta. 419, 87–94 (2013). doi:10.1016/j.cca.2013.02.003 CrossRef

165.

V. DeClercq, J.E. Enns, a Yeganeh, C.G. Taylor, P. Zahradka, Modulation of cardiovascular function by adipokines. Cardiovasc. Hematol. Disord. Drug Targets. 13, 59–72 (2013). http://www.ncbi.nlm.nih.gov/pubmed/22882074

166.

H.S. Mattu, H.S. Randeva, Role of adipokines in cardiovascular disease. J. Endocrinol. 216, T17–T36 (2013). doi:10.1530/JOE-12-0232 PubMedCrossRef

167.

L.A. Kalnina Z, Silina K, Bruvere R, Gabruseva N, Stengrevics A, Barnikol-Watanabe S, Leja M, Molecular characterization and expression analysis of SEREX-defined antigen NUCB2 in gastric epithelium, gastritis and gastric cancer. Eur. J. Histochem. EJH. 53, 7–18 (2009). http://www.ncbi.nlm.nih.gov/pubmed/19351608

Titel: Nesfatin-1: a new energy-regulating peptide with pleiotropic functions. Implications at cardiovascular level
verfasst von: Sandra Feijóo-Bandín
Diego Rodríguez-Penas
Vanessa García-Rúa
Ana Mosquera-Leal
José Ramón González-Juanatey
Francisca Lago
Publikationsdatum: 01.04.2016
Verlag: Springer US
Erschienen in: Endocrine / Ausgabe 1/2016
Print ISSN: 1355-008X
Elektronische ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-015-0819-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2016

Cardiovascular risk in adult hypopituitaric patients with growth hormone deficiency: is there a role for vitamin D?

T regulatory (Treg) and T helper 17 (Th17) lymphocytes in thyroid autoimmunity

Incidence of morphometric vertebral fractures in adult patients with growth hormone deficiency

Factors associated with 1,25-dihydroxyvitamin D3 concentrations in liver transplant recipients: a prospective observational longitudinal study

Relationship between myostatin and irisin in type 2 diabetes mellitus: a compensatory mechanism to an unfavourable metabolic state?